Abuse-Deterrent Exemption From Medicaid Rebates Hinges On FDA Standards

Opioid formulations with abuse-deterrent properties will be exempt from Medicaid price-inflation rebates if they meet FDA standards, Centers for Medicare and Medicaid Services says in guidance to manufacturers.